This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Stable Cell Line Development Market

Stable Cell Line Development Market By Source (Mammalian Cell Line and Non-Mammalian Cell Line), Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering), Cell Lines (Recombinant Cell Lines, Hybridomas, Continuous Cell Lines and Primary Cell Lines), End Users (Hospital, Research Laboratory) & Region - Forecast 2022-2032

Market Insights on Stable Cell Line Development covering sales outlook, demand forecast & up-to-date key trends

Stable Cell Line Development Market Overview

Global stable cell line development demand is anticipated to be valued at US$ 2.5 Billion in 2022, forecast to grow at a CAGR of 10.8%to be valued at US$ 7 Billion from 2022 to 2032.

Report Attribute

Details

Estimated Base Year Value (2021)

US$ 1 Billion

Expected Market Value (2022)

US$ 2.5 Billion

Anticipated Forecast Value (2032)

US$ 7 Billion

Projected Growth Rate (2022-2032)

10.8% CAGR

Stable cell line development is a service that covers the majority of cell cultures. It is primarily used in research and selective diagnosis, and the applications involved in stable cell line development include recombinant protein and antibody production, functional studies, drug screening, gene editing, assay development, and many other platforms.

The procedure entails transferring infected cells to a suitable medium for growth; stability testing is an important step in characterizing cell lines. It ensures the quality of the cell lines produced throughout the passage. The majority of stable cell line development is tailor made in response to institute requirements, ensuring a safe and effective investment. The majority of research activities involving stable cell line development are cancer causes, which makes this market more clinical.

According to the National Cancer Institute at the National Institutes of Health, there were approximately 8.2 million cancer deaths and 14 million new cases in 2012. As a result, efficient stable cell line development is required in modern research activities.

Which are Some Prominent Drivers Spearheading Stable Cell Line Development Market Growth?

The market's expansion has been fueled by rising demand for cell line development in cancer research. Models have traditionally been used for the development of therapeutics in clinical research, and the advantages over stable cell line development result in a positive market outcome.

Companies working on such advancements completely transform the market by replacing traditional cell lines. Researchers, in addition to accepting disease mutations through stable cell line development, tend to focus on new drug development through such cell lines, which would aid in the expansion of the market for stable cell line development.

Companies in the market offer customized cell lines for selective research purposes; this practice allows customers to systematically route their desired end product. Most manufacturers offer price reductions to attract customers and build a loyal customer base. Efficiency and capacity are the two main criteria used to evaluate stable cell line development products, and the greater the product difference, the more market space it will occupy.

The market is influenced by the complexity of advanced stable cell line development procedures. Stable cell line development, on the other hand, being one of the first lines in clinical research, provides an open market with enormous potential to reach its peak.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Challenges Faced by the Stable Cell Line Development Industry?

The stable cell line development market will be hampered by high capital costs and high expenditure required for research and development capabilities. Complexities in the development of stable cell lines will complicate the market's growth rate even more. The absence of a favourable and adequate reimbursement scenario in developing and underdeveloped economies will also dampen market growth rates.

Why is APEJ emerging as an Opportunistic Stable Cell Line Development Market?

Greater China is expected to hold a stellar revenue share in the APEJ stable cell line development market in 2022, with an astronomical CAGR during the forecast period. Increased government funding and private initiatives for research and development programmes for stable cell line development can be attributed to growth.

Furthermore, the widespread acceptance of Chinese Hamster Ovary cells as the first stable mammalian cell for stable cell line development, as well as their widespread acceptance for culturing and manipulation for biopharmaceutical use, will boost market growth in the APEJ region.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is North America Contributing to Growth of the Stable Cell Line Development Market?

According to Future Market Insights, The United States dominated the North American stable cell line development market in 2021, with a total market share of more than 90.8%, and is expected to continue experiencing rapid growth throughout the forecast period.

The increasing demand for monoclonal antibodies for the treatment of COVID-19 infected patients in the region is driving the growth of this market. Furthermore, the absence of non-revised patent rights for major biologics has resulted in the expansion of generic as well as novel stable cell line development processes, fueling sales of stable cell line development in the region.

Market Competition

Some of the major players in the global Stable Cell Line Development Market include GenScrip, Molecular Devices, and LLC. Thermo Fisher Scientific, ProteoGenix, Sino Biological Inc., OriGene Technologies, Inc., and Fusion Antibodies plc.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 10.8% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Source
  • Cell Lines
  • Applications
  • End User 
  • Region

Regions Covered

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan and China
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Russia
  • Poland
  • Australia & New Zealand
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • GenScrip
  • Molecular Devices, LLC.
  • Thermo Fisher Scientific
  • ProteoGenix
  • Sino Biological Inc.
  • OriGene Technologies, Inc.
  • Fusion Antibodies plc.

Customization

Available Upon Request

Key Segments Profiled in the Stable Cell Line Development Industry Survey

By Source:

  • Mammalian Stable Cell Line Development
  • Non-Mammalian Stable Cell Line Development

By Application:

  • Stable Cell Line Development for Bioproduction
  • Stable Cell Line Development for Drug Discovery
  • Stable Cell Line Development for Toxicity Testing
  • Stable Cell Line Development for Tissue Engineering
  • Stable Cell Line Development for Other Applications

By Cell Lines:

  • Recombinant Stable Cell Line Development
  • Hybridomas Stable Cell Line Development
  • Continuous Stable Cell Line Development
  • Primary Stable Cell Line Development

By End Users:

  • Stable Cell Line Development across Hospitals
  • Stable Cell Line Development across Research laboratories
  • Stable Cell Line Development for Other End Users

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan and China
  • Japan
  • Middle East & Africa

Frequently Asked Questions

FMI projects the global Stable Cell Line Development market to expand at a 10.8% value CAGR by 2032

U.S is expected to be the most opportunistic Stable Cell Line Development market, accumulating 90.8% revenue in 2021

GenScrip, Molecular Devices, LLC. Thermo Fisher Scientific, ProteoGenix, and Sino Biological Inc., are some prominent stable cell line development manufacturers

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Stable Cell Line Development Market